MARKET

KTTA

KTTA

Pasithea Therapeutics Corp
NASDAQ
0.7250
-0.0367
-4.82%
Closed 17:15 02/06 EST
OPEN
0.7544
PREV CLOSE
0.7617
HIGH
0.7834
LOW
0.7144
VOLUME
327.18K
TURNOVER
0
52 WEEK HIGH
3.850
52 WEEK LOW
0.2810
MARKET CAP
16.74M
P/E (TTM)
-0.1391
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KTTA last week (0126-0130)?
Weekly Report · 02/02 09:23
Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization
TipRanks · 01/28 21:58
Pasithea Therapeutics Corporation Held Special Shareholder Meeting
Reuters · 01/28 21:19
Weekly Report: what happened at KTTA last week (0119-0123)?
Weekly Report · 01/26 09:23
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)
TipRanks · 01/21 18:00
Weekly Report: what happened at KTTA last week (0112-0116)?
Weekly Report · 01/19 09:26
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway
TipRanks · 01/14 11:56
Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1
Reuters · 01/13 12:22
More
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTA stock methods without spending real money on the virtual paper trading platform.